EHA 2013

 
 
 

Gamla Stan, Stockholm

The 18th Congress of the European Hematology Association took place June 13-16, 2013, in Stockholm, Sweden.

 

New drug on the horizon to treat iron overload

Erilyn Riley Read Article
Published: 06/24/13

Nemeth_Elizabeta_MD_EHA_2013_240.jpg
Elizabeta Nemeth, PhD

Preclinical research suggests that minihepcidin, a peptide mimic of natural hepcidin, plays a therapeutic role in iron overload, in particular ß-thalassemia and hereditary hemochromatosis. And the treatment could be available for human use in a year and a half, according to Elizabeta Nemeth, PhD, of the David Geffen School of Medicine at UCLA. She reviewed the development status of minihepcidin at the 18th Congress of the European Hematology Association in Stockholm. [Read Article]

RBCX decreases complications in pregnant SCD patients

Erilyn Riley Read Article
Published: 06/21/13

pregnant_woman_Credit_Nina_Matthews_230.jpg
Pregnant woman
Credit: Nina Matthews

A retrospective study of 45 women has shown that prophylactic red blood cell exchange (RBCX) during pregnancy decreases complications associated with sickle cell disease (SCD). Ilknur Kozanoglu, MD, of Baskent University Medical Faculty in Ankara, Turkey, presented these findings in a poster session at the 18th Congress of the European Hematology Association (abstract P450). Pregnant SCD patients are at risk of painful pre- and postpartum crises . . . [Read Article]

DLBCL subtype impacts effectiveness of ibrutinib

Erilyn Riley Read Article
Published: 06/20/13

de_Vos_Sven_strt_240.jpg
Sven de Vos, MD, PhD

“One of the most important advances in the last 10 years in diffuse large B-cell lymphoma (DLBCL) has been the identification of a novel molecular classification system,” declared Sven de Vos, MD, PhD, at the 18th Congress of the European Hematology Association. And the interim results of the phase 2 trial of ibrutinib in relapsed or refractory DLBCL illustrate that statement. Dr de Vos, of the UCLA Medical Center in Los Angeles, presented the findings as abstract S1180. [Read Article]

New monoclonal antibody shows promise in MM

Erilyn Riley Read Article
Published: 06/19/13

Lokhorst_Henk_EHA 2013_240_contrast.jpg
Henk Lokhorst, MD

The anti-CD38 monoclonal antibody daratumumab has prompted a 47% response rate in heavily pretreated multiple myeloma patients who have no further treatment options, according to new research. Henk Lokhorst, MD, of the University Medical Center Utrecht in the Netherlands, presented results of this phase 1/2 study as abstract S576 at the 18th Congress of the European Hematology Association in Stockholm. He and his colleagues conducted an open-label, dose-escalation . . . [Read Article]

Prasugrel passes first test in kids with SCD

Erilyn Riley Read Article
Published: 06/18/13

doc-and-patient_Credit_St_Jude_Childrens_Research_Hospital_220.jpg
Doctor examines child with SCD
Credit: St Jude Children’s
Research Hospital

Researchers report that the antiplatelet agent prasugrel has passed its first test in treating children with sickle cell disease (SCD). Prasugrel achieved dose-dependent platelet inhibition in children, with only 3 mild and self-limited hemorrhagic events. Lori Styles, MD, of Children’s Hospital and Research Center in Oakland, California, reported the findings during a poster session (abstract P407) at the 18th Congress of the European Hematology Association in Stockholm. [Read Article]

Quizartinib elicits ‘impressive’ responses in older AML patients

Erilyn Riley Read Article
Published: 06/17/13

Dohner_Hartmut_MD_EHA_2013_240.jpg
Hartmut Döhner, MD

The second-generation FLT3 tyrosine kinase inhibitor quizartinib has demonstrated “quite impressive response rates,” according to a speaker at the 18th Congress of the European Hematology Association. Hartmut Döhner, MD, of the University Hospital of Ulm in Germany, said the rates are particularly striking given the refractoriness of the patient population. All 110 patients in the cohort analyzed had FLT3-ITD-positive acute myeloid leukemia (AML), were 60 . . . [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}